Clinical trial
Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV…
NCT00121199 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00121199 |
|---|---|
| Title | Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma |
| Official title | Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell NHL |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma |
| Intervention type | Biological, Drug, Other |
| Interventions | rituximab, bevacizumab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, prednisone, laboratory biomarker analysis |
| Enrollment | 73 |
| Start date | Jun 1, 2005 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jul 21, 2005 |
| Last update posted | May 21, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: